Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Adjustment of clopidogrel dose

PreclinicalSmall molecule

UUniversity Heart Center Freiburg - Bad Krozingen

Adjustment of clopidogrel dose is one of 2 small molecule programs targeting Platelet Inhibition. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Platelet InhibitionCompleted

Platelet InhibitionPreclinical

Completed

Competition

Competitive Landscape

1 competitor in Platelet Inhibition

#DrugCompanyPhaseTrials

Acetylsalicylic Acid

Adjustment of clopidogrel dose

UUniversity Heart Center Freiburg - Bad Krozingen

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Platelet Inhibition1 trial

Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition

Completed·UUniversity Heart Center Freiburg - Bad Krozingen·N/A·NCT00302913·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Adjustment of clopidogrel dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adjustment of clopidogrel dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adjustment of clopidogrel dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Heart Center Freiburg - Bad Krozingen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Heart Center Freiburg - Bad Krozingen

Related News